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COMMENTARY
Abstract: Two key early 20th century notions, the first the primacy of diastolic pressure in
determining risk, and the second that hypertension is a discrete disorder, have proved to be
incorrect. We now recognize the primacy of systolic pressure as a risk factor for cardiovascular
disease and that hypertension is an arbitrary definition. In the early 21st century, we are moving
away from a dichotomous approach to risk classification, and away from notions of
hypertension and normotension towards an appreciation that blood pressure-related risk is
continuous. In parallel, there has been a paradigm shift from a single risk factor approach to
comprehensive cardiovascular disease risk prevention. Accordingly, prevention of
cardiovascular disease requires a focus on lowering of blood pressure and modification of
associated risk factors rather than simply treatment of hypertension. This emphasis is reflected
in the World Health Organization (WHO) – International Society of Hypertension (ISH) 2003
statement on management of hypertension.
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Introduction
The definition of hypertension has long been recognized to be arbitrary and
problematic, as reflected by the numerous changes in definition over the years. At
about the time of the great “two cultures” debate around the relative values of science
and the humanities (Snow 1959), the great divide in hypertension was the debate
between the two giants of the field in the mid-twentieth century, Pickering and Platt.
The former, whose view ultimately triumphed, held that high blood pressure was
simply the upper end of a continuous distribution, whereas Platt regarded hypertension
as a discrete disorder (Swales 1985). Perhaps the definition that has best stood the
test of time is that hypertension should be defined in terms of blood pressure level
above which investigation and treatment do more good than harm (Evans and Rose
1971).
For much of the 20th century, the emphasis in hypertension was on diastolic
pressure. It is now recognized that systolic pressure is more important as a marker of
risk and that isolated systolic hypertension is itself an important entity (Neaton and
Wentworth 1992). At the same time, there has been downward revision of the definition
of what constitutes hypertension, eg, from 160/100 to 140/90 mmHg over the last
20 years. Indeed JNC 7 now has a pre-hypertensive category (120/80 to 139/89 mmHg)
(JNC 7 2003).
But, more importantly, it is now clear that changes in blood pressure, even over a
range, which by any definition would be regarded as normotensive, are associated
with changes in cardiovascular risk. MacMahon and colleagues (1990) showed
unequivocally that the risk of cardiovascular disease (CVD) was continuously
associated with diastolic blood pressure over 70–110 mmHg and that there was no
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threshold for the association. The same is true of systolic
pressure (MacMahon et al 1990).
The WHO recognized this reality: “Increasingly, the
very terms hypertension, hyperglycemia and hyper-
cholesterolemia will probably disappear, as the focus moves
from treating a theoretically decided cut-off point, towards
managing continuous distributions of risks that intersect and
interact with each other: blood pressure, blood sugar and
blood cholesterol should be the focus of control” (WHO
2002a, p 13).
In that World Health Report (WHO 2002b), the
association of systolic blood pressure (above a theoretical
minimum of 115 mmHg) with CVD risk for stroke, ischemic
heart disease, hypertensive disease, and other cardiac disease
was continuous; and globally, around 62% of cerebro-
vascular disease and 49% of ischemic heart disease was
attributable to suboptimal blood pressure (systolic blood
pressure > 115 mmHg). The report pointed out that blood
pressure ranks third globally, in terms of risk for burden of
disease, behind underweight (number 1) and unsafe sex and
in front of tobacco, alcohol, unsafe water, cholesterol, and
overweight (number 10). It estimated that hypertension
worldwide causes over 7 million premature deaths, 4.5% of
the global disease burden, and some 64 million disability
adjusted life years lost (WHO 2002a).
The World Health Organization (WHO) – International
Society of Hypertension (ISH) statement on management
of mild hypertension was published in 2003 (Kaplan et al
2003), shortly after the European (ESH–ESC 2003) and US
guidelines, JNC 7 (2003).
The three documents were different in purpose with
different target audiences. The WHO–ISH document was a
statement for a global audience, which updated the very
comprehensive 1999 WHO–ISH guidelines (Chalmers et
al 1999) in three key areas:
￿ ascertainment of overall cardiovascular risk to establish
thresholds of, and goals for, treatment;
￿ treatment strategies;
￿ cost-effectiveness.
The other two documents were comprehensive guidelines
for European and North American audiences, respectively.
This difference in target audience is of substantial
practical importance, as the global capacity to access and
manage hypertension is very different from that in the
developed countries of Europe and the USA. A global
capacity assessment of 167 countries by WHO found 61%
had no national hypertension guidelines, 45% did not have
health professionals trained to manage hypertension,
antihypertensives were not affordable in 25% of countries,
basic drugs for hypertension were not available in 12%, and
basic equipment for managing hypertension was not
available in 8% (Alwan et al 2001). Low- and middle-income
countries have limited capacity to address comprehensive
cardiovascular risk, particularly in primary care. Customized
risk assessment and management approaches are essential
for such low resource settings (WHO 2002a, 2002c).
The classifications of hypertension used in the
three documents are summarized in Table 1. The differences
reflect arbitrary division of a continuous risk.
Stratification of risk from the WHO–ISH statement and
the European guidelines is shown in Table 2. Risk
stratification was less prominent in JNC 7. The European
guidelines made the important point that risk in this context
means “added” risk, ie, low risk means low added risk. The
differences between the two charts are more apparent than
real and reflect the emphasis on simplicity in the WHO–
ISH statement, where added risk is low, medium, or high;
whereas the European guidelines use low, moderate, high,
and very high.
Thresholds for treatment were the same in all
three documents, as were targets for blood pressure
lowering. Thresholds are 140/90 mmHg for low- and
medium-risk subjects, but lower for high-risk patients.
Targets are < 140 mmHg systolic in low–medium risk and
< 130/80 mmHg in high-risk patients.
Table 1 WHO, US, and European classifications of
hypertension (mmHg)
WHO–ISH
Grade 1 Grade 2 Grade 3
140–159/ 160–179/ ≥ 180
90–99 100–109 ≥ 110
JNC 7
Normal Pre-HT Stage 1 Stage 2
< 120 120–139/ 140–159/ ≥ 160
< 80 80–89 90–99 ≥ 100
ESH–ESC
Optimal Normal High normal
< 120 120–129/ 130–139/
< 80 80–84 85–89
Grade 1 Grade 2 Grade 3 ISH
140–159/ 160–179/ ≥ 180 ≥ 140
90–99 100–109 ≥ 110 < 90
Abbreviations: ESH–ESC, European Society of Hypertension – European
Society of Cardiology; HT, hypertension; ISH, International Society of
Hypertension; JNC 7, The Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; WHO,
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All three documents recommend lifestyle measures for
prevention and management of hypertension. Recom-
mendations are for weight loss in the overweight, physical
activity, moderation of alcohol intake, healthy diet (fruit,
vegetables, and low saturated fat), reduction of dietary
sodium and increased dietary potassium.
The documents differ in choice of initial therapy. All,
however, agree the emphasis on initial therapy is outdated
because most patients will not be controlled on monotherapy.
The WHO–ISH statement emphasizes that trial data suggest
benefits largely derived from blood pressure reduction, while
recognizing the strong evidence that specific agents benefit
patients with compelling indications. Accordingly, for
patients without compelling indications, on the basis of
comparative trial data, availability, and cost, it recommends
(low dose) diuretic be considered for first-line therapy.
JNC 7 makes a similar recommendation for low dose
diuretic, and adds that if BP is > 20/10 mmHg above target,
then starting with 2 drugs should be considered.
The European guidelines take a different position, and
recommend any of 5 major classes as initial therapy:
diuretics, β-adrenoreceptor blockers, calcium channel
blockers, angiotensin-converting enzyme inhibitors, or
angiotensin receptor blockers.
The three documents give similar compelling indications
for specific drugs. The WHO–ISH statement puts more
emphasis on feasibility and cost-effectiveness, which are
of greater importance globally than in the rich countries of
USA and Europe. It points out that cost-effectiveness equals
benefits for expenditure, whereas affordability equals
prevalence and total cost of treatment in a specific setting.
Thus, where resources are limited, cost-effective treatment
may not be affordable. Where resources are limited, priority
for drug therapy should be given to those at higher risk.
The statement noted that in many (but not all) settings,
thiazide diuretics are cheapest and hence most cost-effective,
but where there are compelling indications, classes that
provide additional benefits, even if more expensive, may
be more cost-effective. In patients with low added risk,
treatment may not be cost-effective unless drugs are cheap,
but in high-risk patients with large benefits from treatment,
even expensive drugs may be cost-effective.
JNC 7 suggests use of generic drugs or combination
drugs should be considered to reduce prescription costs,
whereas the European guidelines state that cost of drugs
should not predominate over individual efficacy and
tolerability.
The WHO–ISH statement reflects the World Health
Report (WHO 2002a) and the WHO–ISH 2000 statement
on prevention (Chockalingam et al 2000) in stressing that
worldwide population strategies to reduce blood pressure
are very cost-effective. The WHO–ISH statement points out
that prevention of CVD requires both population-based and
high-risk group strategies targeting unhealthy lifestyle: diet,
tobacco, inactivity; hypertension, glucose intolerance,
hyperlipidemia; and CVD management.
The three documents, written as they are for different
audiences, vary in emphasis, but their similarities far
outweigh their differences. If we are to prevent and control
the current worldwide epidemic of cardiovascular disease,
Table 2 Stratification of risk
WHO–ISH
BP (mmHg) Grade 1 Grade 2 Grade 3
140–159/ 160–179/ ≥ 180
90–99 100–109
Other risks
Nil Low Medium High
1–2 Medium Medium High
≥ 3/TOD/ACC High High High
ESH–ESC
BP (mmHg) Normal High normal Grade 1 Grade 2 Grade 3
SBP 120–129 or SBP 130–139 or SBP 140–159 or SBP 160–179 or SBP ≥ 180 or
DBP 80–84 DBP 85–89 DBP 90–99 DBP 100–109 DBP ≥ 110
Other risk factors and disease history
No other risk factors Average Average Low Moderate High
1–2 risk factors Low Low Moderate Moderate Very high
3 or more or TOD or diabetes Moderate High High High Very high
ACC High Very high Very high Very high Very high
Abbreviations: ACC, associated clinical conditions; DBP, diastolic blood pressure; SBP, systolic blood pressure; TOD, target organ damage.Vascular Health and Risk Management 2005:1(3) 260
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we need a comprehensive and aggressive approach directed
at both populations and high-risk individuals, focussing on
global risk-factor reduction.
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